Dabigatran Etexilate Reddy
Direct oral anticoagulant (DOAC) — direct thrombin inhibitor for stroke prevention and blood clot treatment
Dabigatran etexilate Reddy is a direct oral anticoagulant (DOAC) that works by directly inhibiting thrombin, a key enzyme in blood clot formation. It is prescribed to prevent stroke in patients with atrial fibrillation, to treat and prevent deep vein thrombosis (DVT) and pulmonary embolism (PE), and to prevent blood clots after hip or knee replacement surgery. As a generic formulation of dabigatran etexilate, it provides the same proven clinical benefits at an accessible cost. This guide covers everything you need to know about its uses, correct dosage, potential side effects, drug interactions, and important safety information.
Quick Facts
Key Takeaways
- Dabigatran etexilate Reddy is a direct thrombin inhibitor used primarily to prevent stroke in patients with non-valvular atrial fibrillation and to treat venous thromboembolism.
- Unlike warfarin, dabigatran does not require routine INR blood monitoring, though kidney function must be checked regularly.
- A specific reversal agent (idarucizumab/Praxbind) is available for emergency situations involving uncontrolled bleeding or urgent surgery.
- Capsules must be swallowed whole — never open, crush, or chew them, as this dramatically increases drug absorption and bleeding risk.
- Renal function is critical for dosing decisions; the drug is primarily eliminated through the kidneys and is contraindicated in severe renal impairment (CrCl <30 mL/min).
What Is Dabigatran Etexilate Reddy and What Is It Used For?
Quick Answer: Dabigatran etexilate Reddy is a prescription blood thinner (anticoagulant) that directly blocks thrombin to prevent blood clots. It is used for stroke prevention in atrial fibrillation, treatment of deep vein thrombosis and pulmonary embolism, and prevention of venous blood clots after joint replacement surgery.
Dabigatran etexilate Reddy belongs to a class of medications known as direct oral anticoagulants (DOACs), specifically categorized as a direct thrombin inhibitor (DTI). The active substance, dabigatran etexilate, is a prodrug that is rapidly converted in the body to its active form, dabigatran. Once activated, dabigatran selectively and reversibly binds to thrombin (coagulation Factor IIa), one of the central enzymes in the coagulation cascade. By blocking thrombin, dabigatran prevents the conversion of fibrinogen to fibrin, the protein mesh that forms the structural basis of blood clots.
This medication was developed as a more convenient alternative to traditional vitamin K antagonists such as warfarin. Unlike warfarin, which requires frequent blood monitoring (INR testing) and has numerous food and drug interactions, dabigatran offers a more predictable pharmacokinetic profile with fixed dosing. The RE-LY trial (Randomized Evaluation of Long-Term Anticoagulation Therapy), one of the largest randomized controlled trials in cardiology, demonstrated that dabigatran 150 mg twice daily was superior to warfarin in preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation, while the 110 mg dose showed non-inferiority with a lower rate of major bleeding.
Dabigatran etexilate Reddy is a generic formulation that contains the same active substance at the same strengths as the original branded product. Generic medications must meet strict bioequivalence standards set by regulatory agencies such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), ensuring they deliver the same therapeutic effect.
Approved Indications
Dabigatran etexilate Reddy is approved for the following clinical indications:
- Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) with one or more risk factors, such as prior stroke or TIA, age 75 years or older, heart failure (NYHA Class II or above), diabetes mellitus, or hypertension.
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adults, and prevention of recurrent DVT and PE, following initial treatment with a parenteral anticoagulant for at least 5 days.
- Primary prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective total hip replacement or total knee replacement surgery.
Atrial fibrillation is the most common sustained cardiac arrhythmia, affecting approximately 33.5 million people worldwide according to the World Health Organization (WHO). Patients with atrial fibrillation have a five-fold increased risk of stroke due to blood clots forming in the heart's atrial appendage. Anticoagulation therapy reduces this stroke risk by approximately 60–70%, making it one of the most important preventive treatments in modern medicine.
What Should You Know Before Taking Dabigatran Etexilate Reddy?
Quick Answer: Before taking dabigatran, your doctor must assess your kidney function, bleeding risk, and current medications. This drug is contraindicated in patients with active pathological bleeding, mechanical heart valves, severe kidney impairment, or those taking certain P-glycoprotein inhibitors concurrently.
Before starting treatment with dabigatran etexilate Reddy, a thorough medical assessment is essential. Your prescribing physician will evaluate several critical factors to determine whether this medication is safe and appropriate for you. The information below outlines the most important considerations, but your doctor will take your complete medical history into account when making prescribing decisions.
Contraindications
- You are allergic to dabigatran etexilate, dabigatran, or any of the other ingredients in the capsule
- You have severely impaired kidney function (creatinine clearance <30 mL/min)
- You currently have active, clinically significant bleeding
- You have a lesion or condition at significant risk of major bleeding (e.g., current or recent gastrointestinal ulceration, malignant neoplasms at high bleeding risk, recent brain or spinal injury, recent brain, spinal, or ophthalmic surgery)
- You have a mechanical prosthetic heart valve
- You are being treated with systemic ketoconazole, cyclosporine, itraconazole, or dronedarone
- You have a liver disease or hepatic impairment that is expected to impact survival
- You are taking another anticoagulant concurrently (e.g., warfarin, rivaroxaban, apixaban) except when switching therapy
Warnings and Precautions
Special care and more frequent monitoring are required in the following situations. Discuss these with your doctor before starting treatment:
- Renal impairment: Approximately 80% of dabigatran is eliminated through the kidneys. Reduced kidney function leads to higher drug levels and increased bleeding risk. Kidney function must be assessed before starting treatment and monitored at least once a year. In patients aged 75 or older or with mild-to-moderate renal impairment (CrCl 30–50 mL/min), monitoring should be performed every 6 months or more frequently if clinically indicated.
- Age 80 years and older: These patients generally receive a lower dose (110 mg twice daily) due to increased bleeding risk associated with advanced age.
- Bleeding risk: Like all anticoagulants, dabigatran increases the risk of bleeding. Conditions that elevate this risk include recent biopsy or major trauma, bacterial endocarditis, thrombocytopenia, platelet disorders, congenital or acquired coagulation disorders, and concurrent use of medications that affect hemostasis (antiplatelet agents, SSRIs/SNRIs, NSAIDs).
- Gastrointestinal effects: Dabigatran is associated with a higher rate of gastrointestinal bleeding compared to warfarin, particularly in patients aged 75 years or older. Dyspepsia and GI discomfort may also occur. Taking the capsules with a full glass of water and with food may help reduce GI symptoms.
- Surgical procedures: Dabigatran must be discontinued before elective surgery or invasive procedures. The timing depends on kidney function and the bleeding risk of the procedure: typically 24 hours before standard-risk procedures (CrCl ≥50 mL/min) and 48–96 hours before high-risk procedures or in patients with reduced kidney function.
- Spinal/epidural anesthesia: There is a risk of spinal or epidural hematoma, which can lead to permanent paralysis. Adequate time must pass after the last dose before catheter placement or removal.
Pregnancy and Breastfeeding
There is limited clinical data on the use of dabigatran during pregnancy. Animal studies have shown reproductive toxicity, including reduced fetal body weight and increased skeletal variations at high exposures. Dabigatran etexilate Reddy should not be used during pregnancy unless clearly necessary and after careful consideration of the potential benefit versus risk by the treating physician.
It is not known whether dabigatran or its metabolites are excreted in human breast milk. A decision must be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of the medication to the mother. Women of childbearing potential should use effective contraception during treatment.
Dabigatran capsules must be swallowed whole with a full glass of water, with or without food. Do not open, crush, break, or chew the capsules. The pellets inside the capsule, if taken without the capsule shell, can increase bioavailability by up to 75%, substantially raising the risk of bleeding. Remove capsules from the blister only immediately before taking them, as the drug is sensitive to moisture.
How Does Dabigatran Etexilate Reddy Interact with Other Drugs?
Quick Answer: Dabigatran is a substrate of P-glycoprotein (P-gp), a transport protein in the gut and kidneys. Strong P-gp inhibitors (ketoconazole, dronedarone, cyclosporine) are contraindicated, while P-gp inducers (rifampicin, St. John’s Wort) can significantly reduce dabigatran levels. NSAIDs and antiplatelet agents increase bleeding risk.
Understanding drug interactions is crucial for the safe use of dabigatran. Unlike warfarin, dabigatran is not metabolized by cytochrome P450 (CYP) enzymes and therefore has fewer food and drug interactions. However, dabigatran etexilate (the prodrug) is a substrate of the efflux transporter P-glycoprotein (P-gp), and interactions with P-gp modulators are clinically significant.
P-glycoprotein acts as a gatekeeper in the intestinal wall and kidneys. Drugs that inhibit P-gp increase the absorption and reduce the renal clearance of dabigatran, leading to higher blood levels and greater bleeding risk. Conversely, P-gp inducers increase the efflux of dabigatran, reducing its blood levels and potentially diminishing its anticoagulant effect.
Major Interactions (Contraindicated or Requires Dose Adjustment)
| Drug / Class | Mechanism | Clinical Effect | Recommendation |
|---|---|---|---|
| Ketoconazole (systemic) | Strong P-gp inhibitor | Increases dabigatran levels by ~140–150% | Contraindicated |
| Dronedarone | Strong P-gp inhibitor | Increases dabigatran levels by ~70–100% | Contraindicated |
| Cyclosporine | Strong P-gp inhibitor | Significantly increases dabigatran levels | Contraindicated |
| Itraconazole | Strong P-gp inhibitor | Significantly increases dabigatran levels | Contraindicated |
| Rifampicin | Strong P-gp inducer | Decreases dabigatran levels by ~65% | Avoid concomitant use |
| St. John’s Wort | P-gp inducer | Reduces dabigatran levels significantly | Avoid concomitant use |
| Carbamazepine, Phenytoin | P-gp inducers | Expected to reduce dabigatran levels | Avoid concomitant use |
Moderate Interactions (Caution / Monitoring Required)
| Drug / Class | Mechanism | Recommendation |
|---|---|---|
| Verapamil | Moderate P-gp inhibitor | Reduce dabigatran dose; take both drugs simultaneously |
| Amiodarone | Moderate P-gp inhibitor | No dose adjustment generally needed; monitor for bleeding |
| Quinidine | P-gp inhibitor | Monitor for signs of bleeding; consider dose reduction |
| Clarithromycin | P-gp inhibitor | Clinical monitoring recommended |
| Ticagrelor | P-gp inhibitor + antiplatelet effect | Avoid unless strictly necessary; increased bleeding risk |
| Aspirin, Clopidogrel | Antiplatelet effect | Increased bleeding risk; use only if clinically indicated |
| NSAIDs (ibuprofen, naproxen) | Antiplatelet + GI mucosal damage | Use short courses only; increased GI bleeding risk |
| SSRIs / SNRIs | Impair platelet function | Monitor for bleeding; especially GI bleeding |
Unlike warfarin, dabigatran does not interact with vitamin K-rich foods (such as green leafy vegetables). There are no dietary restrictions while taking dabigatran. However, avoid grapefruit juice in large quantities as it may have mild P-gp inhibitory effects.
What Is the Correct Dosage of Dabigatran Etexilate Reddy?
Quick Answer: The standard dose for stroke prevention in atrial fibrillation is 150 mg twice daily. A reduced dose of 110 mg twice daily is used for patients aged 80 or older, or those at higher bleeding risk. For VTE prophylaxis after surgery, 220 mg once daily (or 150 mg once daily for higher-risk patients) is typical. Dosage always depends on kidney function.
The dosage of dabigatran etexilate Reddy is individualized based on the indication, the patient's age, kidney function, body weight, concomitant medications, and overall bleeding risk. Below are the recommended dosing regimens according to current European and international guidelines.
Adults — Atrial Fibrillation (Stroke Prevention)
Standard Dose
150 mg twice daily (one 150 mg capsule morning and evening), approximately 12 hours apart. This is the recommended dose for most adults under 80 years of age with CrCl >50 mL/min.
Reduced Dose
110 mg twice daily is recommended for:
- Patients aged 80 years or older
- Patients receiving concomitant verapamil (take both drugs at the same time)
- Patients with CrCl 30–50 mL/min who are at high bleeding risk
- Patients with gastritis, esophagitis, or gastroesophageal reflux
- Other patients at increased risk of bleeding (individual physician assessment)
Adults — DVT/PE Treatment and Prevention of Recurrence
Treatment Phase
150 mg twice daily after at least 5 days of parenteral anticoagulation therapy (e.g., low molecular weight heparin). A reduced dose of 110 mg twice daily should be considered for patients aged 80 years or older or those at elevated bleeding risk.
Adults — VTE Prevention After Surgery
Hip Replacement Surgery
220 mg once daily (taken as two 110 mg capsules together). Start with 110 mg within 1–4 hours after surgery completion, then 220 mg once daily thereafter. Treatment duration: 28–35 days.
Knee Replacement Surgery
220 mg once daily (taken as two 110 mg capsules together). Start with 110 mg within 1–4 hours after surgery completion, then 220 mg once daily. Treatment duration: 10 days.
Reduced Dose for VTE Prevention
150 mg once daily (taken as two 75 mg capsules) for patients aged 75 years or older, those with moderate renal impairment (CrCl 30–50 mL/min), or those receiving concomitant verapamil.
Children
Dabigatran etexilate Reddy is not recommended for use in children and adolescents under 18 years of age for most indications due to insufficient data on safety and efficacy. In some countries, pediatric formulations have received approval for treatment of venous thromboembolism in children, but these utilize weight-based dosing with specific pediatric pellet formulations that differ from adult capsules.
Elderly Patients
Age is one of the most important factors in dabigatran dosing. Patients aged 75–79 years may use the standard dose of 150 mg twice daily for atrial fibrillation, but the 110 mg dose may be preferred if the bleeding risk is judged to be elevated. For patients aged 80 years and older, the 110 mg twice daily dose is recommended as the standard for atrial fibrillation. Close monitoring of renal function is particularly important in elderly patients, as age-related decline in kidney function can significantly affect drug clearance.
Missed Dose
If you miss a dose, take it as soon as you remember, provided there are at least 6 hours remaining before the next scheduled dose. If fewer than 6 hours remain, skip the missed dose and take the next one at the usual time. Never take a double dose to make up for a forgotten capsule. If you are unsure, contact your doctor or pharmacist for advice.
Overdose
Taking more dabigatran than prescribed increases the risk of bleeding, which can be life-threatening. There is no routine antidote to reverse the effects in general clinical settings, but the specific reversal agent idarucizumab (Praxbind) is available in hospital emergency departments. If you suspect an overdose, seek immediate emergency medical care. Activated charcoal may be effective if given within 2 hours of ingestion. Dabigatran can be dialyzed due to its low protein binding (~35%).
| Indication | Standard Dose | Reduced Dose | Duration |
|---|---|---|---|
| Atrial fibrillation (stroke prevention) | 150 mg twice daily | 110 mg twice daily | Long-term |
| DVT/PE treatment | 150 mg twice daily | 110 mg twice daily | 3–6 months or longer |
| VTE prevention (hip surgery) | 220 mg once daily | 150 mg once daily | 28–35 days |
| VTE prevention (knee surgery) | 220 mg once daily | 150 mg once daily | 10 days |
What Are the Side Effects of Dabigatran Etexilate Reddy?
Quick Answer: The most important side effect of dabigatran is bleeding, which can range from minor (nosebleeds, bruising) to serious (gastrointestinal or intracranial hemorrhage). Gastrointestinal symptoms like dyspepsia, nausea, and abdominal pain are common. Serious side effects are uncommon but require immediate medical attention.
Like all medicines, dabigatran etexilate Reddy can cause side effects, although not everybody gets them. The side effects listed below are based on clinical trial data from the large RE-LY, RE-COVER, RE-NOVATE, and RE-MODEL studies, as well as post-marketing surveillance data. Bleeding is the most clinically significant adverse effect of any anticoagulant therapy and the one that requires the most careful monitoring.
If you experience any unusual bleeding, unexplained bruising, blood in your urine or stool, prolonged nosebleeds, vomiting blood, or coughing up blood, contact your doctor immediately. Signs of serious internal bleeding may include unexplained weakness, dizziness, unusual paleness, or headache that is severe or does not resolve.
Common
May affect up to 1 in 10 people
- Gastrointestinal bleeding
- Abdominal pain
- Dyspepsia (indigestion)
- Diarrhea
- Nausea
- Nosebleed (epistaxis)
- Minor bleeding from wounds or injection sites
- Decrease in hemoglobin
Uncommon
May affect up to 1 in 100 people
- Anemia (low red blood cell count)
- Thrombocytopenia (low platelet count)
- Skin rash, pruritus (itching)
- Urticaria (hives)
- Urogenital bleeding (blood in urine)
- Rectal bleeding
- Abnormal liver function tests
- Elevated liver enzymes (ALT/AST)
- Hyperbilirubinemia
- Hemarthrosis (bleeding into joints)
Rare
May affect up to 1 in 1,000 people
- Intracranial hemorrhage (bleeding in the brain)
- Allergic reactions including angioedema
- Bronchospasm
- Alopecia (hair loss)
- Dysphagia (difficulty swallowing — related to esophageal ulceration from capsule lodging)
Not Known (Frequency Cannot Be Estimated)
Reported from post-marketing surveillance
- Anaphylactic reaction
- Esophageal ulcer
- Gastric ulcer
- Retroperitoneal hemorrhage
Seek immediate emergency medical care if you experience any of the following: severe or uncontrolled bleeding from any site, signs of stroke (sudden weakness, difficulty speaking, facial drooping, severe headache), vomiting blood or material that looks like coffee grounds, black or bloody stools, blood in your urine (pink, red, or brown), coughing up blood, or signs of a severe allergic reaction (swelling of face, lips, tongue, or throat, difficulty breathing, skin rash with itching).
It is important to note that while the list above may seem extensive, most patients tolerate dabigatran well. In the RE-LY trial involving over 18,000 patients, the dabigatran 150 mg group had significantly fewer intracranial hemorrhages compared to warfarin (0.30% vs. 0.74% per year), which is one of the most feared complications of anticoagulation therapy. The overall rate of serious adverse events leading to treatment discontinuation was comparable between dabigatran and warfarin. Gastrointestinal symptoms (particularly dyspepsia) were more common with dabigatran but typically mild and manageable.
How Should You Store Dabigatran Etexilate Reddy?
Quick Answer: Store below 30°C (86°F) in the original blister packaging to protect from moisture. Do not transfer capsules to pill organizers. Once a blister strip is opened, use the capsules within 30 days. Keep out of reach of children.
Proper storage of dabigatran etexilate Reddy is essential to ensure the medication remains effective and safe throughout its shelf life. Dabigatran capsules are particularly sensitive to moisture, which can degrade the active ingredient and reduce the drug's efficacy.
- Temperature: Store at temperatures not exceeding 30°C (86°F). Do not refrigerate or freeze.
- Moisture protection: Keep the capsules in the original blister packaging until immediately before use. Do not transfer capsules to pill boxes, weekly organizers, or other containers, as exposure to moisture and air can degrade the medication.
- Once opened: After opening the blister package, use the capsules within 30 days. Mark the date of opening on the packaging as a reminder.
- Child safety: Keep this medicine out of the sight and reach of children.
- Expiry date: Do not use this medicine after the expiry date printed on the packaging. The expiry date refers to the last day of that month.
- Disposal: Do not dispose of medicines via household waste or wastewater. Return unused or expired medicines to your pharmacy for safe disposal according to local regulations.
If you notice any change in the appearance of the capsules (such as discoloration, softening, or an unusual odor), do not take them and consult your pharmacist. Damaged or compromised capsules may not deliver the correct dose of medication.
What Does Dabigatran Etexilate Reddy Contain?
Quick Answer: Each hard capsule contains dabigatran etexilate (as mesilate) as the active ingredient, along with tartaric acid, hypromellose, and other excipients. The capsule shell is made from hypromellose and contains colorants including titanium dioxide.
Understanding the complete composition of your medication is important, particularly if you have known allergies or intolerances to any pharmaceutical excipients. Below is the detailed composition of dabigatran etexilate Reddy capsules.
Active Substance
Each hard capsule contains dabigatran etexilate (as mesilate salt), corresponding to 75 mg of dabigatran etexilate. Higher-strength capsules (110 mg and 150 mg) contain proportionally more active substance.
Excipients (Inactive Ingredients)
- Capsule contents: Tartaric acid, acacia (gum arabic), hypromellose, dimethicone, talc, hydroxypropylcellulose
- Capsule shell: Hypromellose, carrageenan, potassium chloride, titanium dioxide (E171), indigo carmine (E132) — colorants may vary by strength
- Printing ink: Shellac, propylene glycol, iron oxide black (E172), potassium hydroxide
Tartaric acid is included as a key excipient because it creates an acidic microenvironment that enhances the dissolution and absorption of dabigatran etexilate, which is poorly soluble at neutral pH. This formulation approach ensures consistent bioavailability regardless of gastric pH, which is particularly important in elderly patients who may have reduced gastric acid production or who take proton pump inhibitors.
Dabigatran etexilate Reddy capsules do not contain lactose, gluten, or sucrose. However, they do contain potassium chloride. Patients on a potassium-restricted diet should discuss this with their healthcare provider, although the amount per capsule is negligible. If you are allergic to any of the excipients listed above, do not take this medicine and consult your doctor about alternative anticoagulation options.
Frequently Asked Questions About Dabigatran Etexilate Reddy
Medical References & Sources
All information in this article is based on peer-reviewed medical literature, international clinical guidelines, and regulatory documents. The following sources were consulted:
- Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151. doi:10.1056/NEJMoa0905561 (RE-LY Trial)
- European Medicines Agency (EMA). Pradaxa (dabigatran etexilate) — Summary of Product Characteristics (SmPC). Last updated 2024.
- U.S. Food and Drug Administration (FDA). Pradaxa Prescribing Information. Boehringer Ingelheim Pharmaceuticals, Inc. Revised 2024.
- Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation. Eur Heart J. 2021;42(5):373–498. doi:10.1093/eurheartj/ehaa612
- Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342–2352. doi:10.1056/NEJMoa0906598 (RE-COVER Trial)
- Pollack CV, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal — full cohort analysis. N Engl J Med. 2017;377(5):431–441. doi:10.1056/NEJMoa1707278 (RE-VERSE AD Trial)
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd List (2023). Geneva: World Health Organization; 2023.
- British National Formulary (BNF). Dabigatran etexilate. National Institute for Health and Care Excellence (NICE). Updated 2025.
- Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–1676.
- Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018;154(5):1121–1201.
Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, comprising licensed physicians with specializations in hematology, cardiology, clinical pharmacology, and internal medicine. Our team follows the GRADE framework for evidence assessment and adheres to the editorial standards of leading medical organizations.
Content developed by physicians with expertise in anticoagulation therapy and clinical pharmacology, following WHO, EMA, and FDA guidelines.
Independently reviewed by the iMedic Medical Review Board. All claims verified against peer-reviewed literature and current clinical guidelines.
Level 1A evidence from systematic reviews and randomized controlled trials (RE-LY, RE-COVER, RE-VERSE AD). GRADE quality assessment applied.
No pharmaceutical industry funding or sponsorship. All content is editorially independent with no conflicts of interest.